AVITA Medical, Inc. (RCEL) Misses Q4 EPS by 10c, provides guidance

AVITA Medical, Inc. (NASDAQ: RCEL) reported Q4 EPS of ($0.44), $0.10 worse than the analyst estimate of ($0.34). Revenue for the quarter came in at $18.4 million versus the consensus estimate of $23.2 million.

GUIDANCE:

AVITA Medical, Inc. sees FY2025 revenue of $100-106 million, versus the consensus of $89.7 million. Expect to generate free cash flow in the second half of 2025 and reach GAAP profitability during Q4 2025

For earnings history and earnings-related data on AVITA Medical, Inc. (RCEL) click here.

You May Also Be Interested In

• Apollo Global Management (APO) call put ratio 1 call to 6.8 puts a focus on a spreader of 9K contracts January 95 and 135 puts
• Omnicom launches Acxiom Fan Graph sports marketing platform
• Navan signs travel and expense deal with Viessmann Generations Group